Negara: Kanada
Bahasa: Inggris
Sumber: Health Canada
VALPROIC ACID
TEVA CANADA LIMITED
N03AG01
VALPROIC ACID
500MG
CAPSULE (ENTERIC-COATED)
VALPROIC ACID 500MG
ORAL
100/500
Prescription
MISCELLANEOUS ANTICONVULSANTS
Active ingredient group (AIG) number: 0112996003; AHFS:
MARKETED
2007-07-13
PRODUCT MONOGRAPH PR RATIO-VALPROIC (VALPROIC ACID) Capsules Capsules (250 mg and 500 mg) USP Antiepileptic Teva Canada Limited 30 Novopharm Court Toronto, Ontario Canada M1B 2K9 www.tevacanada.com Date of Preparation : July 24, 2013 Submission Control No: 166248 2 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .............................................................. 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 4 WARNINGS AND PRECAUTIONS ......................................................................................... 5 ADVERSE REACTIONS ......................................................................................................... 16 DRUG INTERACTIONS ......................................................................................................... 19 DOSAGE AND ADMINISTRATION ..................................................................................... 26 OVERDOSAGE ....................................................................................................................... 28 ACTION AND CLINICAL PHARMACOLOGY ................................................................... 29 STORAGE AND STABILITY ................................................................................................. 32 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................... 32 PART II: SCIENTIFIC INFORMATION .................................................................................... 33 PHARMACEUTICAL INFORMATION ................................................................................. 33 CLINICAL TRIALS ................................................................................................................. Baca dokumen lengkapnya